Andrew Newland
Chief Executive

Andrew Newland is Chief Executive of ANGLE plc. He has an MA in Engineering Science from the University of Cambridge and is a qualified Chartered Accountant. He has 18 years of medical diagnostics experience and has specialised in the liquid biopsy space for the last nine years.

He has led the development of technology-based businesses based on strong intellectual property for over 28 years and for the last 18 years he has been Chairman or on the Board of several specialist medical technology companies. After working with the engineering conglomerate, TI plc, he worked for KPMG from 1982 to 1994; from 1985 to 1987 he was based in the US as a manager providing corporate finance and business advice to high technology firms in the area around Route 128, Boston, Massachusetts. During this time, he led KPMG’s involvement in the IPO of the medical technology company Cardio Data Inc. From 1987 to 1994 he worked for KPMG in the UK with responsibility for establishing KPMG’s UK and European High Technology Practices and High Technology Consulting Group.

Andrew founded ANGLE in 1994. In 1999, Andrew led the team that founded the medical diagnostic company, Acolyte Biomedica. Acolyte was the first ever spin-out of the Defence Science and Technology Laboratory (Dstl) Porton Down, which specialised in rapid diagnosis of MRSA the ‘hospital super-bug’. Andrew chaired the company for several years and successfully led the company through three major rounds of venture capital investment. Andrew also founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nutrition research institute. Andrew chaired the Board of Provexis, a specialist nutraceutical company with a heart-health product, through to its successful flotation in 2005.


Paul Smith
Vice President; CEO ANGLE Biosciences, Inc.

Paul Smith is the CEO of ANGLE Biosciences, Inc.. Prior to joining ANGLE, Paul most recently served as President and CEO of Axela Inc. a company specializing in the development of multiplex biomarker tools. He has more than 30 years of experience in the life science instrumentation field with a diverse background in sales, marketing and field operations.

A major focus has been commercializing new technologies through collaborative partnerships with academic, pharmaceutical and industrial clients. Previously, Mr. Smith held the positions of Vice-President, Sales Europe and North America and Director, European Operations for Ciphergen Biosystems Inc., a company focused on translating proteomics-based biomarker discoveries into high value research and clinical diagnostic assays.

Ian Griffiths
Chief Financial Officer

Ian Griffiths is the Finance Director of ANGLE plc. He has specialised in technology commercialisation for over 30 years and is an expert on the development and growth of new technology-based businesses. Ian has a BSc in Mathematics with Management Applications from Brunel University and is qualified as a chartered accountant. For seven years he worked for KPMG, initially in accountancy with a special work focus, then in management consulting within KPMG's High Technology Consulting Group where he specialised in financial modelling, business planning, corporate finance, market development and strategy work.

Ian joined ANGLE in 1995. As well as leading the finance function at ANGLE plc, he has been closely involved with the development and delivery of the former UK, US and Middle East Consulting and Management services businesses and in developing new Ventures, both third-party and ANGLE’s own. Ian has been heavily involved in the start-up phase and also the ongoing development of ANGLE’s own ventures by working closely with management on business plans, financial and operational management, fund raising and commercial aspects, including both medical and physical sciences companies. He is currently leading the financial development of ANGLE’s major medical diagnostic business Parsortix.

Michael O’Brien
Business Development Director

Michael has extensive experience of commercialising new technologies, with a solid background in strategic and operational leadership. Michael joined ANGLE in 2009 to lead a government backed technology incubator. The incubator evaluated more than 60 early stage technology companies from around the UK before selecting the highest potential start-ups and providing intense consultancy support in setting technology milestones, developing an effective business model, building collaborations and securing early customers.

The technology incubator helped companies to raise in excess of £45m private investment and also put in place a number of corporate relationships to fast-track technology to market. Prior to ANGLE, Michael gained eight years leadership experience, as Strategy and Operations director of a media company, during which time he led its merger with a sister company to form and then launch a new £4.5m company known as RadioCentre. During this time Michael chaired a number of highly successful cross industry collaboration projects. Michael’s early career was spent at Diageo within the Corporate Strategy department where he focused on manufacturing and technology strategy, both in the UK and in operational business units in Indonesia, Australia and Singapore. Michael has an MA in Engineering Science from the University of Cambridge and an MBA from the University of Warwick, specialising in technology commercialisation. Michael has been leading ANGLE’s European business development since 2014.

Martin Cooke
Director of Manufacturing & Regulatory Affairs

Martin is the Head of Manufacturing and Regulatory at ANGLE plc, a Chartered Engineer and holds an MEng degree in Electrical and Electronic Engineering from The University of Nottingham. He joined ANGLE in 2004 and first specialised in technology commercialisation and knowledge transfer projects supporting businesses, particularly involving universities and other specialist knowledge and research centres.

Martin’s early career  was spent as a practicing design engineer  in the military, instrumentation and telecommunications sectors with particular experience in high-precision analogue measurement techniques, intrinsic safety and embedded systems. Having progressed through a number of senior technical and commercial positions, Martin became the Product Manager  of a multi-million dollar  international product family at a global telecommunications equipment provider. In this role he was responsible for product concepts, new product development and market introductions,  together with associated transition to stable manufacturing and supply. The role also encompassed on-going technical support for existing products and a large, established customer base. Martin has been Head of Manufacturing and Regulatory since 2013.

Craig Miller
Clinical Studies Director

Craig Miller joined ANGLE in March of 2016 as the Clinical Studies Director, where he is responsible for driving the clinical development activities of ANGLE. He has over 20 years of experience in the RUO and IVD diagnostics industry, including clinical trial management, clinical data management, biostatistics, regulatory submissions, and manuscript writing and editing (Craig is a co-author on over 80 peer-reviewed publications in the field of oncology and diagnostics).

Prior to joining ANGLE, Craig was the Vice President of Clinical Development at Saladax Biomedical, where he was responsible for the design, implementation, and execution of clinical studies for the validation of novel therapeutic drug monitoring assays (MyCare®) in the field of oncology. Before that, he was the Associate Director of Clinical Research for the Veridex Oncology Biomarkers team at Janssen R&D, a Johnson & Johnson company, where he was responsible for the design, implementation, coordination, and execution of clinical research and development trials for the evaluation, characterization, and commercialization of circulating tumor cell (CTC) assays and technologies. During his 12 year tenure with Veridex/Janssen R&D (formerly Immunicon Corporation), Craig was instrumental in obtaining de-novo FDA clearance of the CELLSEARCH® system and associated components (i.e. CELLTRACKS® AUTOPREP® and CELLTRACKS® ANALYZER® instruments, CELLSAVE preservative tube, and CELLSEARCH® CTC Kits). As the Director of Clinical Affairs and Biostatistics at Fujirebio Diagnostics, Inc., he played a key role in the clinical validation and FDA clearance of the MESOMARK® and ROMA® assays. Craig started his career in diagnostics at UroCor (now Dianon Pathology, a division of LabCorp), where he held positions of increasing responsibility in Research & Development for new and innovative products in the detection, prognosis, and monitoring of urologic diseases (primarily prostate and bladder cancer). Craig has a BS in Biochemistry from Texas A&M University.

Nick Claxton
Vice President Commercial Operations

Nick Claxton is VP Commercial Operations for ANGLE plc, and is responsible for forging corporate relationships and developing global distribution networks to commercialise ANGLE’s products and services.

Nick has over 35 years’ experience within the diagnostic and biotech industry, having started as a Scientific Officer at Charing Cross Hospital Fulham, covering Haematology, Histology, Microbiology he specialised in Biochemistry. After leaving the NHS, Nick joined the UK premier diagnostic distributor, Laboratory Impex and was responsible for launching Bactec, an automated blood culture system for Becton Dickinson, Tecan liquid handling robotics, and AVL blood gas analysers into the UK.

Nick joined Becton Dickinson where he held the position of Business Director responsible for sales, marketing, client and technical services for 10 years. From there he moved to Roche as head of marketing, following the acquisition of Boehringer Mannheim. In 2000 Nick joined LGC (formerly Laboratory of the Government Chemist) as Director of Forensics, responsible for the 7 geographical laboratory sites along with the sales and marketing for the group. The role required direct relationships with the UK Government Home Office and the 43 constabularies of the UK and Northern Ireland.

In 2007 Nick joined the UK Board of Olympus Scientific as Scientific Director with responsibilities for the Clinical Chemistry and Microscopy divisions. In 2010 Nick became Business Director for a start-up company called Epistem, where they launched the first hand held PCR device (Genedrive) developed for field based TB testing along with other infectious diseases.

In 2015 Nick joined another start up, Premaitha Health as Chief Commercial Officer. Premaitha were the first company to achieve a CE/IVD for non invasive pre natal testing using next generation sequencing platforms.

Nick is also a non-executive director of two companies, MEMP ( Middle East Medical Portal) which helps small British medical companies enter the Middle East and Inception Associates which mentors early start ups through business planning and raising investment.